GSK Removes Blenrep From U.S. Market, Due Poor Clinical Trial Performance for Multiple Myeloma Drug
Blenrep failed to meet the goals of a confirmatory clinical trial required by the FDA to keep its accelerated approval license.
November 23, 2022 By: Irvin Jackson
Blenrep failed to meet the goals of a confirmatory clinical trial required by the FDA to keep its accelerated approval license.
A Depo-Provera meningioma lawsuit filed by a Virginia woman indicates she will have to undergo MRIs every year for the rest of her life after a 2.5 cm tumor was surgically removed from her brain.
Lawyers are currently completing discovery in a group of 15 Bard PowerPort lawsuits, which will then be narrowed down to six potential trial claims by mid-April 2025.
Plaintiffs and defendants involved in hair relaxer lawsuits have filed competing plans which differ in how they would select 16 cases to serve as bellwether early test cases, and also differ in when they would be ready for trial.
"*" indicates required fields